"Our mission has always been to provide compassionate, personalized care in a setting where patients feel heard and respected," Dr. Youtsos added. "Having a dermatology-certified nurse practitioner on ...
K2 Vision has performed 5,000 Light Adjustable Lens (LAL) procedures. RxSight, the company that makes the lens, has recognized K2 Vision as the highest-volume LAL practice in the world. The Light ...
Phentolamine ophthalmic solution 0.75% is marketed in the United States as RYZUMVI ® for the treatment of pharmacologically induced mydriasis. The supplemental approval expands its approved ...
CALGARY, Alberta, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Whole Lotta Dank (WLD), a Canadian cannabis brand development and sourcing platform, officially launches Dank Pack, the first brand to debut from ...
The latest 600-participant study adds to Bacomind's clinical evidence, with findings reported by Natural Remedies indicating potential benefits for memory and cognitive function. The research may help ...
The company’s clinical data provide another important piece of the investment narrative. In August, NeOnc reported topline results from a 24-patient Phase 2a study of NEO100, including six-month ...
At this year's meeting, Integra will showcase its growing portfolio of ENT technologies and instruments, including the ACCLARENT AERA® Eustachian Tube Treatment, TruDi® Navigation System, MicroFrance® ...
Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, ...
U.S. FDA-approved Indications Libtayo is a prescription medicine used to treat: ...
Each pack contains seven mini joints, totaling 2.1 grams of THCa flower. The collection includes multiple strains and reflects Hemp Hop's broader focus on flower quality, consistency, and product ...
Aprea’s lead program, APR-1051, is an oral, small-molecule WEE1 kinase inhibitor being evaluated in the ongoing Phase 1 ACESOT-1051 study in patients with biomarker-defined advanced solid tumors.
With positive topline six-month data now reported from the REMAIN-1 Pivotal Cohort, Fractyl is advancing toward its remaining anticipated 2026 milestone, a potential DeNovo regulatory submission, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results